An interventional study of Low-Load Blood Flow Restriction Training (LL-BFRT) + Aerobic Exercise and Sham Low-Load Blood Flow Restriction Training (LL-BFRT) + Aerobic Exercise in Chronic Obstructive Pulmonary Disease (COPD) and Blood Flow Restriction Training (BFRT), sponsored by Inonu University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Inonu University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey — 58 open to participants now, 68 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Turkey.
Among the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, this one is the 157th largest by planned enrollment of the 188 interventional ones that give a count, is one of 16 that started in 2026, is one of 122 with no phase, reaches primary completion later than 52 of the 67 other live ones, and was the 235th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →58 of the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey are open now. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–75
University of Yalova · Sites in Turkey
Ages 18+
Çanakkale Onsekiz Mart University · Sites in Turkey
Ages 40+
Istinye University · Sites in Turkey
Ages 40–80
AstraZeneca · Sites in Turkey
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 45 · Phase 4 12
First in 2002; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 72 across the 188 interventional studies, 77 across the 60 observational. Of the 164 that completed or were terminated, 39 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 248 have an industry lead sponsor. The 10 most frequent:
Inonu University is the lead sponsor of 399 studies on the registry; 98 are open to participants now.
Inonu University has 5 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
12 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07581132Akdeniz UniversityInvestigation of the Effect of Structured Energy Conservation Techniques Training on COPD Patients | 2026-12-10 |
| NCT05738720Saglik Bilimleri UniversitesiEffect of Home Based Pulmonary Rehabilitation on Exacerbation and Hospital Admission in Severe COPD | 2026-12-20 |
| NCT07469111Inonu UniversityEffects Of Low-Load Blood Flow Restriction Training Of The Upper Extremity In Patients With Chronic Obstructive Pulmonary Disease | 2026-12-25 |
| NCT07087626Erzurum City HospitalCOPD Assessment Test Score and Perioperative Risk in COPD | 2027-01-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent airflow limitation, progressive dyspnea, and peripheral muscle dysfunction, significantly impairing functional capacity and quality of life. Although the combined implementation of aerobic and resistance exercises is recommended in pulmonary rehabilitation programs, early-onset ventilatory limitation in individuals with COPD often hinders tolerance to high exercise intensities. This limitation increases the need for alternative exercise approaches targeting peripheral muscle adaptations. Low-load blood flow restriction training (LL-BFRT), which enables improvements in muscle strength with low mechanical loads, has emerged as a potential option for this patient population. However, evidence regarding the effects of LL-BFRT in individuals with COPD-particularly on upper extremity muscles-remains limited.
The aim of this study is to comparatively investigate the effects of LL-BFRT and sham-BFRT, both administered in addition to an aerobic exercise program in individuals diagnosed with stage II and III COPD, on upper extremity muscle strength, upper extremity functional capacity, activities of daily living performance, quality of life, functional exercise capacity, muscle oxygenation, and respiratory parameters. The study is designed as a randomized controlled, single-blind, quasi-experimental interventional trial.
The expected outcomes are that LL-BFRT may enhance upper extremity muscle strength and functional capacity, improve activities of daily living and quality of life, and increase exercise tolerance due to its applicability at low mechanical loads. Furthermore, findings related to muscle oxygenation and respiratory parameters are anticipated to provide clinical evidence regarding the physiological effects of LL-BFRT on peripheral muscle adaptations. These results are expected to guide the integration of LL-BFRT as an alternative and safe approach in upper extremity exercise prescription within pulmonary rehabilitation programs, support clinical decision-making processes, and establish a scientific foundation for future research.
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and irreversible airflow limitation resulting from airway and/or alveolar abnormalities, usually caused by prolonged exposure to noxious particles or gases (1). COPD represents one of the leading causes of mortality among chronic respiratory diseases and is recognized as a major global health problem, affecting approximately 10% of the adult population, with an increasing incidence associated with population aging. According to the 2017 Global Burden of Disease (GBD) Study, the global mortality rate attributable to COPD was 41.9 deaths per 100,000 population, accounting for 5.7% of all-cause mortality. The mortality rate was reported as 46.7 per 100,000 in men and 37.0 per 100,000 in women (2).
The progressive and persistent airflow limitation in COPD, together with reduced parenchymal elasticity, increases ventilatory demand and imposes an excessive load on the respiratory muscles. Hyperinflation further reduces the effective contractile range of these muscles, creating a vicious cycle in which mechanoreceptor stimulation enhances ventilatory drive and exacerbates dyspnea. Increased dyspnea and impaired respiratory muscle function limit the performance of activities of daily living (ADLs), leading to substantial reductions in physical performance (3).
Skeletal muscle dysfunction is a frequent systemic manifestation of COPD. Reductions in peripheral muscle strength involving the upper and lower extremities as well as the trunk significantly limit exercise capacity and functional performance, negatively affecting overall health status. Importantly, impaired muscle strength has been identified as a strong predictor of morbidity, mortality, disability, and exacerbation risk, independent of the degree of airway obstruction (4).
During upper extremity activities, individuals with COPD frequently experience marked dyspnea and dynamic hyperinflation, which significantly restrict functional independence and highlight the clinical importance of upper extremity functional capacity (5). Compared with healthy peers, individuals with COPD demonstrate reduced performance during upper limb activities and report substantial difficulty. This limitation is partly attributable to altered respiratory mechanics, as upper extremity muscles also function as accessory respiratory muscles. Consequently, dyspnea intensifies during upper limb activity, often leading to premature termination of exercise (6).
Given the dyspnea-inducing nature of upper extremity use and its negative impact on activity tolerance, preserving and improving upper extremity function constitutes a critical rehabilitation target in COPD. Indeed, as emphasized in the most recent joint official statement by the American Thoracic Society (ATS) and the European Respiratory Society (ERS), the inclusion of upper extremity exercise training in pulmonary rehabilitation programs is strongly supported for individuals with COPD (7).
Pulmonary rehabilitation programs commonly incorporate aerobic modalities such as arm ergometry, as well as resistance-based approaches using multi-station systems, elastic bands, or free weights to target upper extremity function (8). Although aerobic exercise forms the cornerstone of pulmonary rehabilitation, its effects on muscle strength and mass are considered limited. Therefore, combined aerobic and resistance exercise approaches are recommended to more effectively address peripheral muscle dysfunction (9).
However, whether currently tolerated training intensities-often limited by ventilatory constraints-are sufficient to optimally target peripheral muscle dysfunction remains controversial. Both the ATS and ERS have highlighted the need for innovative rehabilitation strategies capable of targeting peripheral muscle dysfunction at lower mechanical loads (10). Traditional moderate-to-high intensity resistance training may be effective but is often poorly tolerated in individuals with COPD due to dyspnea, early fatigue, and ventilatory limitation, thereby limiting adherence and long-term participation (11).
In this context, low-load blood flow restriction training (LL-BFRT) has emerged as a promising alternative. Despite the use of low mechanical loads, LL-BFRT induces localized ischemia and increased metabolic stress, leading to significant gains in muscle strength and hypertrophy. This method may represent a viable option for individuals with COPD who are unable to tolerate high mechanical loads (12).
Although evidence supporting LL-BFRT primarily derives from studies conducted in healthy individuals and predominantly targeting lower extremity muscles (12-14), data regarding its application to upper extremity muscles in individuals with COPD remain limited. Considering that upper limb activities impose greater ventilatory demand and trigger dyspnea earlier, the potential advantages of LL-BFRT in this region warrant investigation. This research gap underscores the necessity of evaluating the effectiveness of LL-BFRT-based upper extremity resistance training in COPD.
Aim of the Study The aim of this study is to comparatively investigate the effects of LL-BFRT and sham-BFRT, administered in addition to an aerobic exercise program, on upper extremity muscle strength, upper extremity functional capacity, performance of activities of daily living, quality of life, functional exercise capacity, muscle oxygenation, and pulmonary function parameters in individuals diagnosed with stage II and III COPD.
Interventions Participants in both groups will undergo an exercise program twice weekly for 8 weeks.
Both groups will perform upper extremity aerobic exercise using an arm cycle ergometer. Each session will begin with a 5-minute warm-up at 0 Watts, followed by 20 minutes of aerobic exercise at 60-70% of age-predicted maximum heart rate. Initial resistance will be set between 35-50 Watts and maintained within this range according to individual exercise tolerance. Dyspnea will be monitored using the Modified Borg Scale. A 5-minute cool-down at 0 Watts will follow the aerobic phase.
Intervention Group (LL-BFRT) In addition to aerobic exercise, participants in the intervention group will receive LL-BFRT. A pneumatic cuff will be placed proximally on the upper extremity. Occlusion pressure will be set at 30-40% of arterial occlusion pressure (AOP). Resistance will be set at 30% of one-repetition maximum (1RM). Exercises will follow a standardized 4-set protocol (30-15-15-15 repetitions) with 45-second inter-set rest periods, during which cuff pressure will be maintained.
Targeted muscle groups will include the biceps brachii, triceps brachii, and anterior deltoid. After completion of each exercise, cuff pressure will be released for a 5-minute reperfusion period before proceeding to the next exercise. Dyspnea will be closely monitored using the Modified Borg Scale, and exercise will be terminated if dyspnea reaches ≥6, indicating exercise intolerance.
Control Group (Sham-BFRT) Participants in the control group will receive the same aerobic exercise protocol and identical resistance exercise structure. However, cuff pressure during sham-BFRT will be set at a level insufficient to produce therapeutic blood flow restriction.
Assessments Demographic data including age, sex, height, and weight will be recorded. Body mass index (BMI) will be calculated. Smoking history will be documented in pack-years. Disease duration and COPD stage (according to GOLD classification) will be determined from medical records. Oxygen therapy and inhaled treatment use will be recorded. Exacerbation frequency, defined as the number of exacerbations and hospital admissions within the past 12 months, will also be documented.
This study is expected to provide evidence regarding the clinical efficacy and physiological mechanisms of LL-BFRT in improving upper extremity function in individuals with COPD and to inform exercise prescription within pulmonary rehabilitation programs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals aged 40-80 years with stage 2 and 3 diagnosed according to GOLD criteria
Exclusion Criteria:
Uncontrolled hypertension
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an 8-week upper extremity aerobic exercise program combined with low-load blood flow restriction training targeting upper extremity muscles.
Other: Low-Load Blood Flow Restriction Training (LL-BFRT) + Aerobic Exercise
Participants will receive the same 8-week upper extremity aerobic exercise program combined with sham blood flow restriction training with non-therapeutic cuff pressure.
Other: Sham Low-Load Blood Flow Restriction Training (LL-BFRT) + Aerobic Exercise
Participants will undergo an 8-week upper extremity aerobic exercise program combined with low-load blood flow restriction training (LL-BFRT). The aerobic exercise will be performed using an arm cycle ergometer at 60-70% of age-predicted maximum heart rate for 20 minutes, preceded and followed by 5 minutes of unloaded cycling. In addition, LL-BFRT will be applied to the proximal upper extremity with a pneumatic cuff at 30-40% of arterial occlusion pressure. Resistance exercises will be performed at 30% of one-repetition maximum (1RM) using a 4-set protocol (30-15-15-15 repetitions) with 45-second inter-set rest periods while maintaining cuff pressure. Target muscles include the biceps brachii, triceps brachii, and anterior deltoid.
Participants will undergo the same 8-week upper extremity aerobic exercise program as the intervention group. Aerobic exercise will be performed using an arm cycle ergometer at 60-70% of age-predicted maximum heart rate for 20 minutes, preceded and followed by 5 minutes of unloaded cycling. In addition, sham blood flow restriction training will be applied with a pneumatic cuff placed proximally on the upper extremity. The cuff pressure will be set at a level insufficient to produce therapeutic blood flow restriction. The exercise structure, sets, repetitions, and muscle groups targeted will be identical to the intervention group.
Upper Extremity Functional Capacity
Upper extremity functional capacity and endurance will be assessed using the 6-Minute Pegboard \& Ring Test (6-PBRT). During the test, participants will be seated in front of a pegboard and instructed to use both hands simultaneously to transfer as many rings as possible from two lower pegboards positioned at shoulder level to two upper pegboards located 20 cm above, and then back to the lower boards. The test duration is 6 minutes. Prior to the actual test, participants will be allowed to practice by transferring a few rings to familiarize themselves with the procedure. During the test, the physiotherapist will provide standardized verbal encouragement every minute to motivate the participant. At the end of the 6 minutes, the total number of rings transferred throughout the test will be recorded as the final score (16).
Time frame: Pre- and post-intervention (week 8).
Pulmonary Function Assessment
Pulmonary function will be assessed using spirometric measurements. Spirometry is a standard pulmonary function test that evaluates lung volume and airflow rates. During the test, participants will be instructed to exhale forcefully and completely to achieve maximal lung emptying. Parameters including Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), and the FEV1/FVC ratio will be recorded. In addition, post-bronchodilator FEV1/FVC \< 0.70 will be used for diagnosis and classification in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (18).
Time frame: Pre- and post-intervention (week 8).
Muscle Strength Assestment
Muscle strength of the biceps brachii, triceps brachii, and anterior deltoid muscles will be assessed using a Hand-Held Dynamometer (HHD). Measurements will be performed in standardized seated positions at specific joint angles. Biceps brachii strength will be measured with the elbow flexed at 90° and the forearm in supination (19). Triceps brachii strength will be measured during maximal isometric elbow extension, and anterior deltoid strength during shoulder flexion at 90°. Three measurements will be taken for each muscle group and the highest value will be recorded for analysis.
Time frame: Pre-post ıntervention (week 8)
Activity Of Daily Living Assestment
Activities of daily living will be evaluated using the Londrina Activities of Daily Living (Londrina ADL) Scale. This protocol includes five activities involving upper and lower extremity movements as well as trunk flexion, inclination, and rotation. Participants will sit in front of a table and transfer ten objects of different weights (250 g, 500 g, and 1 kg) from one side of the table to the other using both hands and then return them to the initial position. Participants will also walk three consecutive times over a 6-meter distance as part of the protocol. The total time required to complete all activities will be recorded as the outcome measure.
Time frame: Pre-post ıntervention (week 8)
Quality Of Life Assestment
Quality of life will be assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ is a disease-specific quality of life instrument consisting of 50 items and three domains. The Symptoms domain evaluates the frequency and severity of respiratory symptoms; the Activity domain assesses the impact of respiratory problems on daily activities; and the Impacts domain measures the psychosocial and functional effects of the disease on the individual's life. Response options for the items range between 2 and 5 points, and each item is weighted according to its predefined scoring algorithm during calculation (23).
Time frame: Pre-post ıntervention (week 8)
Functional Capacity
Functional capacity will be assessed using the 6-Minute Walk Test (6MWT). Participants will be instructed to walk as far as possible for 6 minutes, and standardized verbal encouragement will be provided every minute throughout the test. Participants will be allowed to rest as needed; however, they will be encouraged to resume walking as soon as possible. Individuals requiring long-term oxygen therapy or those with resting hypoxemia may receive their usual oxygen flow during the test. Oxygen saturation will be continuously monitored using pulse oximetry (SpO₂) via a finger probe throughout the test. At the end of the test, the total walking distance will be recorded (24).
Time frame: Pre-post ıntervention (week 8)
Muscle Oxygenation Measurement
Muscle oxygenation will be assessed using the Moxy Monitor, a portable device based on near-infrared spectroscopy technology. The device emits light waves into the tissue and detects scattered light using photodetectors placed at different distances from the light source. The detected signal is analyzed using an algorithm based on the Beer-Lambert law to determine oxygenated and deoxygenated hemoglobin levels, allowing the calculation of total hemoglobin (THb) and muscle oxygen saturation (SmO₂). Since light entering larger microvessels is assumed to be fully absorbed, the detected signal mainly originates from capillaries; therefore, the measurements reflect local muscle oxygenation and microvascular oxygen utilization.
Time frame: Pre-post ıntervention (week 8)
Plan to share: No — Participant data will be securely stored by the investigators and may be shared with authorized personnel if deemed necessary, in accordance with applicable privacy regulations.
Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 10 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →